comparemela.com

Latest Breaking News On - Mrna covid 19 vaccine - Page 1 : comparemela.com

From the archives: Erin Richards says data from Pfizer shows it lied

Advocate Erin Richards agreed to spearhead an HC action to prove Pfizer jabs given to millions of SAs were neither “safe” nor “effective”.

South-africa
South-african
South-africans
Alec-hogg
Erin-richards
Pfizer
High-court
Advocate-erin-richards
Conspiracy-theorist
Adv-erin
Adv-erin-richards
Mrna-covid-19-vaccine

Pfizer's bedfellow BioNTech equally culpable in fatally flawed mRNA vaccine manufacturing

This article reveals how Pfizer’s bedfellow BioNTech – in respect of the Pfizer BioNTech mRNA COVID-19 vaccine – is just as culpable.

Germany
United-states
Maschine
Sachsen
Wuhan
Hubei
China
American
German
Sasha-latypova
George-santayana
Davido-fischer

Study finds 29% of teenagers develop heart problems following second dose of Pfizer's mRNA COVID-19 vaccine

A new study from Thailand has found that 29 percent of children who received Pfizer's mRNA Wuhan coronavirus (COVID-19) vaccine suffered heart-related effects afterward. The researchers [.]

United-kingdom
Philadelphia
Pennsylvania
United-states
Thailand
Thai
Scotland
America
Anish-koka
Peter-mccullough
Health-ranger
Pfizer

India's first mRNA Covid-19 vaccine likely to be available soon

The Drugs controller general of India (DCGI) is expected to give Emergency Use Authorisation to Gennova s mRNA vaccine any time soon

India
Emergency-use-authorisation
Mrna-covid-19-vaccine
Covid-vaccine
Indias-first-mrna-covid-19-vaccine
Gennovas-mrna-vaccine

DCGI grants emergency use authorisation to India's first mRNA Covid-19 vaccine: Sources

The Subject Expert Committee under India s drug regulator has found data submitted by Gennova Biopharmaceuticals

Delhi
India
Expert-committee-under-india
Union-government
Expert-committee
Drugs-controller-general
Pune-based-gennova-biopharmaceutical
Subject-expert-committee
Emergency-use-authorisation
Gennova-biopharmaceuticals
Mrna-covid-19-vaccine

vimarsana © 2020. All Rights Reserved.